Practical Barriers in Cancer Immunotherapy Treatment

Traci SuSong, MBA/HCM, CPC, COC, CPhT, CRCR

Department Manager, Cleveland Clinic

Disclosures

- I have nothing to disclose

- I will not be discussing non-FDA approved indications during my presentation.

IO Pipeline and Research

- Current products on the market are the "tip of the iceberg" when looking at manufacturers' Immuno-Oncology (I-O) pipelines

- During the next few years, we can expect a new IO product or indication every few months

- Not only new products, but a myriad of new combinations and regimens

Total number of approved immunotherapy indications

Strategies for New Information

- ## Immuno-Oncology Champion
  - Identify an "Immuno-Oncology Champion" from among your providers to be the "I-O point person" responsible for all product questions and staff education (can be physician, advance practitioner or pharmacist)

- ## Education group
  - Identify a core group within your practice to manage patient education, including the review of existing patient materials and/or the development of new materials specific to I-O agents and management of their adverse effects

- ## Staff education
  - Proactively update staff on new information and consider use of manufacturer-provided resources including on-site training/education (or attend programs like this!)

Manage Reimbursement/Finances

- New-to-market I-O agents may not yet have specific J-Code
  - Ensure a process is in place for appropriate management/billing until J-Code is assigned or, in the case of Hospital Outpatient Prospective Payment Services, a C-Code (Temporary = C9399)

- Identify a point person from within your financial or reimbursement staff to focus on I-O agents and understand the nuances of the various patient support programs
  - Manufacturer benefits verification programs, replacement programs, co-pay support programs, co-pay foundations, and patient assistance programs

- Ensure your practice has sufficient Patient Advocacy
  - Most practices have found that Financial Counselors/Medication Assistance Coordinators pay for themselves many times over; if you are not sure if you have enough, it's a good time to conduct an analysis

Develop Approval Process

- High dollar medication approval process
    - Full benefits investigation, utilize pharma services if offered and allowed per hospital/institution policy
    - Prioritize staff resources to enroll every viable patient into a support program, regardless of on or off-label

- Robust off-label policy and procedure
    - All off-label requests require predetermination
    - Patients are made aware of risks and benefits, including financial risk
    - Patients are required to sign an ABN or NONC
    - Peer review process for appeal if needed

High Dollar Process

Treatment includes high dollar medication → **Clinic nurse obtains signatures for Pharma reimbursement form from patient and prescriber** → **Pharma form is scanned to reimbursement specialists (RS)** → **Pharma form is submitted to company by RS**

On Label Request

Off Label Request

Full benefits investigation performed by Pharma services and referral to copay and PMAP resources provided if necessary

Patient coverage verified by RS

Refer to Off label policy and procedure

Request submitted to payer for approval

Denied

Approved

RS communicates with pharmacist and team once authorization is approved → Patient scheduled for therapy

Follow account to ensure payment and application of copay assistance

Medication Assistance Program Coordinator (MAPC) speaks with patient about benefits and need for copay or PMAP assistance → MAPC assists with copay or PMAP assistance → Coordinate with business office to submit copay grants

© 2019–2020 Society for Immunotherapy of Cancer

Medicare

- Most Medicare Administrative Contractors (MAC) have at least one I-O agent Local Coverage Determination (LCD)

- Some MAC have separate LCD for all agents
  - Cigna Government Services (CGS) published atezolizumab LCD within the first six weeks of release of the agent

- No successful reimbursement outside the FDA label indications

Off-label medication process: *Medicare pre-treatment*

1. Before off-label use is considered, a **risk/benefit conversation** (medical, financial risks) needs to occur with the patient

2. If patient and treating physician wish to proceed, pharmacist and reimbursement specialist work together to gather **sufficient evidence** for off-label use

3. Medication assistance coordinator, reimbursement specialist, and clinical team **determine payment options**
   - Manufacturer assistance/replacement options
   - Medicare payment

4. Patient and the team decide **whether to proceed** with off-label use

Off-label medication process

5. After the patient receives off-label therapy, the **claim is submitted** to Medicare

6. If the claim is not immediately approved, up to **5 levels of appeals** are allowed

7. If claim is ultimately denied, financial counselors arrange for **payment** of the Medicare allowed amount

Commercial Payers

- Policies primarily based upon published scientific evidence

- Clinical policy guidelines and pathways
  - Vendor Pathways examples: Well Point, New Century Health, AIM
  - Clinical policies examples: Anthem, Aetna, UHC, Cigna, Humana

- Often the clinical policies require medication eligibility restrictions beyond the label and additional criteria to be met in order to assure reimbursement
  - Example: Anthem clinical policy for nivolumab includes patient's current ECOG score 0-2 be met

Commercial Payers

- Use of maximum dosages regardless of weight
  - Maximum allowable units per day and per date span for specialty drugs
- Use of National Drug Code (NDC) units versus CPT/Healthcare Common Procedure Coding System (HCPCS) units creates confusion and concern for underpayment
  - J code represents the amount of drug per billing unit
    - 1 J code per medication
    - J code established by CMS
  - NDC represents the manufacturer and size of the vial
    - 1 NDC code for each vial size for each manufacturer
    - NDC code established by FDA and manufacturer
  - Monitor closely for errors in underpayment

Commercial Payers

- Disproportionate approvals of total billing units versus doses for a specific period of time
  - Example: Authorization for 90 mg pembrolizumab for 6 infusions but date range is for nine months - Make sure that the dates and authorizations match
- Always pursue authorization/pre-determination for IO's, regardless of whether the therapy is on or off-label
  - Retrospective denials often occur, particularly for off-label uses, even when there was a pre-determination in acceptance of the use

Commercial Payers

- Billing for waste with immuno-oncology agents
  - Proper usage of the JW modifier
    - JW modifier will indicate the amount of waste volume represented
    - I-O agents that are single-use vials or single-use package for unused portion are eligible
    - Multi-dose vials are not eligible (and currently not available)
  - Not all payers will pay for waste or only pay for part
  - Some payers do not allow rounding of doses and do not pay for waste (a lose/lose situation for providers)
  - Proper documentation necessary in the medical record for discarded waste
    - Mandated wastage rationale for any JW lines on Medicare claims on January 1, 2017

Off-label medication process: *Commercial payers*

1. Before off-label use is considered, a **risk/benefit conversation** (medical, financial risks) needs to occur with the patient.

2. Pharmacist and reimbursement specialist work together to submit **pre-determination request** to payer.

3. If denied, an **appeal** can be filed.

4. If still denied, if there is sufficient evidence for off-label use, reimbursement specialist and medication assistance coordinator **explore payment options.**

5. Patient and team decide **whether to proceed** with off-label use

6. Managed care, reimbursement specialist, and CFO determine the appropriate amount for the **patient to deposit** toward the treatment

7. Patient submits deposit and **off-label treatment is given**

Denials – Common Reasons

- Lack of pre-certification or authorization
- Medical necessity
- Experimental and investigational
- Requires additional information
- Non-covered service/medication on the plan benefit
- Out of network provider
- Timely filing of claims
- Multiple diagnoses coding for disease states and metastases - payer does not apply correct codes to medications
- Error in number of units billed to payer
- Insurance duplicity or delay

General Rules for Denials

- Discover the root cause of the denial
  - Review payer-specific policy, local coverage determinations, national coverage determinations (LCDs & NCDs)
  - Determine if pre-certification or prior authorization was completed
  - Review documentation
    - Reimbursement is linked to the quality of the bill
    - Coders obtain information from medical record but sometimes required information is missing
- Look for denial trends with payers
  - Drugs, diagnosis, charge threshold
- Exceeds total units allowable

Handling Denials

- Work with Finance to develop a method for routing denials to appropriate personnel
  - Leverage IT to create work queue and notification process

- Consider appropriateness of resources
  - Workload (average number of denials/appeals)
  - Strict appeal timelines of many payers

- Consider training/experience of personnel
  - Ideally a nurse or pharmacist with oncology experience
  - Ability to learn and understand financial systems and processes
  - Ability to navigate electronic medical record

Handling Denials

- Request medical peer-to-peer interaction
  - Offer additional information and rationale to discuss with clinical reviewers who made initial determination

- Monitor for trends
  - Increased denials for repetitive reasons may require payer, billing or provider education

- Hold payer accountable
  - Regardless of the size of the organization
    - Example: Payer not recognizing authorization because it came from a third party administrator and denying claims for reason of "lack of pre-certification"

Handling Denials

- Challenge outdated payer policies
  - Develop reconsideration packet (for both commercial payer and Medicare) with evidence to support addition of covered diagnoses and/or regimens excluded from payer policies

Practical barriers beyond payment

- IO-related medical emergencies

- Biosimilars

- CAR T treatments

- Newly approved therapies
  - Payer policies not updated

IO Management Strategies

- Develop protocols
  - Use your "I-O Champion" to take the lead in developing/revising any treatment protocols that may be impacted by the addition of new I-O therapies in your practice

- Patient education
  - Educate all patients on an I-O therapy to clearly identify themselves as such; make sure that these patients can be quickly identified as being on an I-O therapy in their medical record

- Staff education
  - Ensure staff understand and can identify the most common adverse events associated with I-O products, and know when these events could be potentially be life-threatening and/or require immediate clinical attention

Biosimilars

- FDA requires biosimilars to be highly similar, but not identical, to reference product

- Has to demonstrate no clinically meaningful differences in efficacy, safety, and potency

- Primarily tested through non-clinical pathways – examining structural and functional nature of the product

Clinical Studies

Clin Pharm

Pre-clinical

Analytical

CONVENTIONAL approval pathway

Clinical Studies

Clin Pharm

Pre-clinical

Analytical

BIOSIMILAR approval pathway

Biosimilars approved by the FDA

Cancer-related Biosimilar	Reference Product	Approval Date
Zarxio (filgrastim-sndz)	Neupogen (filgrastim)	March 2015
Mvasi (bevacizumab-awwb)	Avastin (bevacizumab)	September 2017
Ogivri (trastuzumab-dkst)	Herceptin (trastuzumab)	December 2017
Fulphilia (pegfilgrastim-jmdb)	Neulasta (pegfilgrastim)	June 2018
Nivestym (filgrastim-aafi)	Neupogen (filgrastim)	July 2018
Truxima (rituximab-abbs)	Rituxan (rituximab)	November 2018
Herzuma (trastuzumab-pkrb)	Herceptin (trastuzumab)	December 2018
Ontruzant (trastuzumab-qyyp)	Herceptin (trastuzumab)	March 2019
Kanjinti (trastuzumab-anns)	Herceptin (trastuzumab)	June 2019

Biosimilar	Reference Product	Approval Date
Inflectra (infliximab-dyyb)	Remicade (infliximab)	April 2016
Erelzi (etanercept-szzs)	Enbrel (etanercept)	August 2016
Amjevita (adalimumab-atto)	Humira (adalimumab)	September 2016
Renflexis (infliximab-abda)	Remicade (infliximab)	May 2017
Cyltezo (adalimumab-adbm)	Humira (adalimumab)	August 2017
Ixifi (infliximab-qbtx)	Remicade (infliximab)	December 2017
Retacrit (epoetin alfa-epbx)	Procrit (epoetin alfa)	May 2018
Hyrimoz (adalimumab-adaz)	Humira (adalimumab)	October 2018
Udenyca (pegfilgrastim-cbqv)	Neulasta (pegfilgrastim)	November 2018
Eticovo (etanercept-ykro)	Enbrel (etanercept)	April 2019

Biosimilars – practical considerations

- Healthcare providers, pharmacists, and patients are critical for biosimilar acceptance and usage

- Substitution policies vary by state – "interchangeable products" can be substituted without prescriber input

- Incentives to prescribe biosimilars from Medicare

Unique considerations for CAR T therapies

- Large up-front cost instead of smaller costs over time

- Potential side effects can lead to large costs as well

- Medicare coverage:
  - Currently local contractor decides whether to cover treatment
  - NCD proposal: in-patient setting if patients are enrolled into a registry or clinical trial with 2 years of post-treatment monitoring
  - "Coverage with Evidence Development"

Best Practices – What is working

- Join ListServs
  - FDA.gov Notifications/Alerts
    - Hematology/Oncology (Cancer) Approvals & Safety Notifications
- Manufacturer's Healthcare Processional websites
  - Medication information, billing codes, NDC, indications
- Payer policy & LCD reviews
  - Partner with contract specialists
- Communicate with clinicians and practice managers/administrators
  - Changes, requirements, education
- Engage your team; share information
  - Training
  - SME on the team

Future Considerations

- Payer ability to keep up with accelerating evidence-based new indications (e.g., new lines of therapy, new tumor types)

- Increasing utilization of checkpoint inhibitors in combination with a host of agents (e.g., chemo, targeted, immunotherapeutic)

- Potential for coverage policies to be biomarker driven (e.g., PD-L1 overexpression)

- Financial implications of agents becoming first line

- Emergence of biosimilars and CAR T treatments